Evidence map›Paper›PMID 30810286›Full record

ArticleThoracic cancer2019

ING5 inhibits lung cancer invasion and epithelial-mesenchymal transition by inhibiting the WNT/β-catenin pathway.

Xin-Li Liu, Jin Meng, Xu-Tao Zhang, Xiao-Hua Liang, Feng Zhang, Guan-Ren Zhao, Tao Zhang

Open access · goldAbstract read
In one paragraph

Article in Thoracic cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Long non-coding RNA SNHG11 regulates the Wnt/β-catenin signaling pathway through rho/ROCK in trabecular meshwork cells.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2023
    Article
  8. Investigation of the effects of phthalates onFrontiers in endocrinology · 2023
    Article
  9. Review
  10. Article
  11. The roles of ING5 in cancer: A tumor suppressor.Frontiers in cell and developmental biology · 2022
    Review
  12. Review
  13. Overexpression ofExperimental and therapeutic medicine · 2021
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Xin-Li LiuDepartment of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
Jin MengDepartment of Pharmacology, School of Pharmacy Key Laboratory of Gastrointestinal Pharmacology of Chinese Materia Medica of the State Administration of Traditional Chinese Medicine, Fourth Military Medical University, Xi'an, China.
Xu-Tao ZhangDepartment of Pharmacology, School of Pharmacy Key Laboratory of Gastrointestinal Pharmacology of Chinese Materia Medica of the State Administration of Traditional Chinese Medicine, Fourth Military Medical University, Xi'an, China.
Xiao-Hua LiangDepartment of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
Feng ZhangDepartment of Pharmacology, School of Pharmacy Key Laboratory of Gastrointestinal Pharmacology of Chinese Materia Medica of the State Administration of Traditional Chinese Medicine, Fourth Military Medical University, Xi'an, China.
Guan-Ren ZhaoDepartment of Pharmacy, PLA No. 309 Hospital, Beijing, China.
Tao ZhangDepartment of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.ORCID 0000-0002-7251-1622
State Administration of Traditional Chinese Medicine of the People's Republic of China · CNAir Force Medical University · CNPLA 306 Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundING5 is the last member of the Inhibitor of Growth (ING) candidate tumor suppressor family that has been implicated in multiple cellular functions, including cell cycle regulation, apoptosis, and chromatin remodeling. Our previous study showed that ING5 overexpression inhibits lung cancer aggressiveness and epithelial-mesenchymal transition (EMT), with unknown mechanisms.

methodsWestern blotting was used to detect total and phosphorylated levels of β-catenin and EMT-related proteins. Immunofluorescent staining was used to observe E-cadherin expression. Proliferation and colony formation, wound healing, and Transwell migration and invasion assays were performed to study the proliferative and invasive abilities of cancer cells.

resultsING5 overexpression promotes phosphorylation of β-catenin at Ser33/37, leading to a decreased β-catenin protein level. Small hairpin RNA-mediated ING5 knockdown significantly increased the β-catenin level and inhibited phosphorylation of β-catenin S33/37. Treatment with the WNT/β-catenin inhibitor XAV939 inhibited ING5-knockdown promoted proliferation, colony formation, migration, and invasion of lung cancer A549 cells, with increased phosphorylation of β-catenin S33/37 and a decreased β-catenin level. XAV939 also impaired ING5-knockdown-induced EMT, as indicated by upregulated expression of the EMT marker E-cadherin, an epithelial marker; and decreased expression of N-cadherin, a mesenchymal marker, and EMT-related transcription factors, including Snail, Slug, Twist, and Smad3. Furthermore, XAV939 could inhibit the activation of both IL-6/STAT3 and PI3K/Akt signaling pathways.

conclusionING5 inhibits lung cancer invasion and EMT by inhibiting the WNT/β-catenin pathway.

Indexed as

A549 Cellsbeta CateninCell Line, TumorCell MovementCell ProliferationEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHCT116 CellsHeterocyclic Compounds, 3-RingHumansLung NeoplasmsNeoplasm InvasivenessPhosphorylationProteolysisTranscription FactorsTumor Suppressor Proteinsbeta CateninCTNNB1 protein, humanHeterocyclic Compounds, 3-RingING5 protein, humanTranscription FactorsTumor Suppressor ProteinsXAV939Epithelial-mesenchymal transition (EMT)ING5lung cancerphosphorylationWNT/β-catenin

Identifiers

PMID30810286
PMCPMC6449261
OpenAlexW2917238746

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.